The U.S. Food and Drug Administration has granted fast track designation to the investigational therapy LBL-034 to facilitate ...

The FDA granted fast track designation to IBI3003 for patients with relapsed/refractory multiple myeloma after receiving four-plus lines of therapy.

Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma ...

The FDA has granted fast track designation (FTD) to LBL-034, an investigational GPRC5D/CD3 bispecific T-cell engager (BiTE), for patients with relapsed/refractory multiple myeloma (R/R MM).

Roberto Mina, MD, discusses the distinguishing factors of the MajesTEC-3 and MajesTEC-9 trials of teclistamab in multiple ...

Data shows iberdomide combination therapy delivers progression free survival and safety in relapsed and refractory multiple ...

All-oral therapies provide an attractive treatment option for patients with relapsed/refractory multiple myeloma, given their administration, the convenience of outpatient dosing, and the decreased ...

Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed ...

A Prescription Drug User Fee Act target date of July 10, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application ...

Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Sham Mailankody, MBBS, discusses results from the long-term follow-up of CARTITUDE-1 ...

The treatment of relapsed/refractory multiple myeloma dramatically changed in recent years with the emergence of therapies such as chimeric antigen receptor (CAR) T-cell products and antibody-drug ...